Johnson & Johnson is reportedly in advanced talks to acquire Ollin Biosciences, a privately held eye-disease developer, for up to $3.4 billion. The deal would include an upfront payment of $2.2 billion, with an additional $1.2 billion contingent on clinical milestones related to Ollin’s lead candidate OLN324. The Financial Times broke the story Sunday, and an agreement could be announced as soon as Monday, though the discussions remain ongoing and the transaction is not yet certain.
What J&J Is Actually Buying
OLN324 is a higher-potency, smaller-format, higher-molar-dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for diabetic macular edema and wet age-related macular degeneration. Those are two of the most common causes of vision loss in older adults. The science matters here because Ollin is not chasing the market with a me-too molecule. OLN324’s anti-Ang2 potency has been described by the company as being substantially higher than faricimab, the current market-leading treatment for these retinal diseases.
Ollin reported positive topline results from its head-to-head Phase 1b JADE study comparing OLN324 to Roche’s faricimab in over 160 patients. OLN324 demonstrated faster and greater improvements in retinal anatomy and numerically greater vision gains compared to faricimab in diabetic macular edema, including superior retinal drying and faster central subfield thickness improvements. Global Phase 3 trials in both indications are expected to begin in the second half of 2026. J&J is buying in just as the most expensive part of development begins.
The Market J&J Is Entering
Retinal disease is a large and growing arena, but it is not unguarded territory. Regeneron Pharmaceuticals held approximately 25% market share in 2025. Roche/Genentech held approximately 20% of the market in 2025, led by Vabysmo and supported by a broader ophthalmology platform. Those two incumbents together hold nearly half the market, and both are upgrading their core franchises. Market size estimates vary by definition, but one widely cited industry forecast puts the retinal biologics market at about $27.25 billion in 2026. There is room for a well-differentiated entrant, but J&J will need OLN324’s Phase 3 data to hold up against two deeply entrenched rivals with established physician relationships.
The Cash Question for JNJ Holders
This is where dividend investors need to pay attention. J&J’s balance sheet can absorb the check, but it is not writing it from surplus. The balance of cash, cash equivalents and current marketable securities was $17.228 billion at the end of the fiscal third quarter of 2026. Against that, the company’s own filings list approximately $9.0 billion remaining on talc, $3.2 billion of corporate bonds due, approximately $2.6 billion for the Sail option, and $0.9 billion of opioid settlements, totaling roughly $15.7 billion in known obligations. A $2.2 billion upfront payment to Ollin’s investors would absorb most of whatever cushion sits above those commitments.
Over the nine months through September 27, 2026, J&J generated $18.85 billion of operating cash flow against $9.585 billion in dividends and $5.958 billion in buybacks. Free cash flow is real and substantial. The company expects approximately $21 billion in free cash flow for the full year. So the Ollin price tag is roughly one-tenth of annual free cash generation. That is fundable. The harder question is whether it is better than buybacks at a time when Stelara is facing biosimilar competition and the talc cash has not yet left the building.
Why This Probably Makes Sense Anyway
The acquisition aligns with J&J’s broader strategy of expanding its pharmaceutical portfolio through targeted acquisitions, following recent deals including the $1 billion purchase of Firefly Bio and the $14.6 billion acquisition of Intra-Cellular Therapies. Management has been consistent on this point: buy science early, run it through J&J’s commercial infrastructure, and generate returns that exceed what buybacks can deliver at current valuations.
Buybacks return capital but do not replace revenue. OLN324, if Phase 3 confirms Phase 1b, would give J&J a credible next-generation asset in a market growing at a mid-to-high single-digit annual rate, anchored by an aging global population that will keep creating new patients. The acquisition would expand J&J’s exposure to retinal disease treatments, complementing its existing vision business, including contact lenses.
What to Watch
The $1.2 billion in milestones tells you where J&J is placing the risk. If OLN324’s Phase 3 data disappoint, the company pays $2.2 billion for a pipeline that never reaches market. That is a real downside scenario in a category where Regeneron and Roche have both spent years optimizing physician comfort with their own molecules.
For long-term JNJ holders, the thesis has not changed. J&J took $5.5 billion of pre-tax charges in Q3 2026 for a proposed resolution of its ovarian talc litigation, and still raised its full-year outlook. The 64-year dividend streak reflects a business built to absorb body blows without cutting. Adding Ollin is a growth bet, not a defensive one. Whether the bet pays is a question Phase 3 data will answer, probably not before 2028.

